Vincristine, bleomycin, mitomycin C, cisplatin combination chemotherapy as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix

Prog Clin Biol Res. 1985;201:225-37.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / adverse effects
  • Bleomycin / therapeutic use
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / radiotherapy
  • Carcinoma, Squamous Cell / therapy*
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Female
  • Humans
  • Middle Aged
  • Mitomycin
  • Mitomycins / adverse effects
  • Mitomycins / therapeutic use
  • Radiotherapy / adverse effects
  • Risk
  • Uterine Cervical Neoplasms / mortality
  • Uterine Cervical Neoplasms / radiotherapy
  • Uterine Cervical Neoplasms / therapy*
  • Vincristine / adverse effects
  • Vincristine / therapeutic use

Substances

  • Mitomycins
  • Bleomycin
  • Mitomycin
  • Vincristine
  • Cisplatin

Supplementary concepts

  • BOMP protocol